Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Rhea-AI Summary

Curis (Nasdaq: CRIS) priced a public offering with certain new and existing healthcare-focused institutional investors for 3,733,334 shares of common stock (or pre-funded warrants in lieu thereof) plus accompanying warrants to purchase up to 3,733,334 shares at a combined price of $1.50 per share and warrant, or $1.49 per pre-funded warrant and warrant.

The common warrants have a $1.75 exercise price, are exercisable immediately and expire five years from issuance; pre-funded warrants have a $0.01 exercise price and are exercisable immediately until fully exercised. Curis expects gross proceeds of about $5.6 million, before fees and expenses, to fund research and development, working capital and general corporate purposes. Closing is expected around August 14, 2026, subject to customary conditions.

Positive

• Gross offering proceeds expected of approximately $5.6 million
• Proceeds designated to fund research and development and corporate needs

Negative

• Issuance of 3,733,334 new shares or pre-funded warrants dilutes equity
• Additional potential dilution from warrants for up to 3,733,334 shares
• Net proceeds reduced by placement agent fees and offering expenses

News Explained

The priced financing could dilute existing holders while delivering Curis about $5.6 million gross if it closes around August 14.

Curis has priced the offering, but it has not closed; the company expects closing on or about August 14, 2026, subject to market conditions and customary conditions.

If completed, it would provide Curis approximately $5.6 million in gross proceeds before expenses while adding 3,733,334 shares or pre-funded warrants and warrants for up to 3,733,334 more shares, creating potential dilution for existing common holders.

Issuing additional shares reduces an existing holder's percentage ownership absent offsetting changes; the pre-funded warrants have a $0.01 exercise price and are immediately exercisable, while the common warrants have a $1.75 exercise price and are immediately exercisable for five years.

The expected $5.6 million gross proceeds equal 56 days of the last reported quarterly operating cash use at the first-quarter 2026 rate.

The Form S-1 was declared effective on August 12, 2026; it registers the securities for sale, but registration alone does not sell them.

The near-term resolution is whether the offering closes around August 14, 2026 and whether the final prospectus discloses terms differing from the announced pricing.

Sources and calculations

• Curis public offering pricing release (2026-08-13)
• Dilution definition (2026-07-17)
• Pre-funded warrant definition (2026-07-17)
• Form S-1 purpose (2026-07-17)
• Curis first-quarter 2026 fundamentals (2026Q1)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $5,600,000 / ($9,001,000 / 90) = 56 days

Argus Aug 13 session 48 alerts

+11.08% close to close 461.4x rel. volume Open Argus

Details

News Market Reaction – CRIS

+31.6% Peak Tracked

-17.7% Trough Tracked

$6.01M Market Cap

On Aug 13, the day this news came out, CRIS closed 11.08% above the previous close. Argus tracked a peak move of +31.6% during that session. Argus tracked a trough of -17.7% from its starting point during tracking. Our momentum scanner recorded 48 alerts for this stock that day. Relative volume reached 461.4x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 13 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the "Offering"). The common warrants will have an exercise price of $1.75 per share, will be exercisable immediately and will expire five years from the issuance date. The pre-funded warrants will have an exercise price of $0.01 per share and will be exercisable immediately until exercised in full.

The gross proceeds from the Offering are expected to be approximately $5.6 million, before deducting placement agents fees and estimated Offering expenses payable by Curis. The Company intends to use the net proceeds of this Offering to fund its research and development activities and for working capital and general corporate purposes The Offering is expected to close on or about August 14, 2026, subject to market conditions and the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as the lead placement agent and Laidlaw & Company (UK) Ltd. is acting as co-placement agent in connection with the Offering.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-298203) filed on August 10, 2026 and declared effective by the Securities and Exchange Commission (the "SEC") on August 12, 2026. The Offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus related to the offering was filed with the SEC on August 10, 2026. The final prospectus related to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering, when available, may be obtained from: A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. The final terms of the offering will be disclosed in a final prospectus to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948).

Cautionary Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws, including without limitation, statements regarding the timing of the completion, and anticipated gross proceeds, of the offering, the use of proceeds for the offering and the terms of the common warrants and pre-funded warrants. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "likelihood", "continue," "potential," "opportunity," "focus," "strategy," "mission," or similar expressions. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions "Risk Factor Summary" and "Risk Factors" in our most recent Annual Report on Form 10-K and the factors that are discussed in other filings that Curis periodically makes with the SEC. In addition, any forward-looking statements represent the views of Curis only as of the date of this press release and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-inc-announces-pricing-of-5-6-million-public-offering-302850642.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key terms of the Curis (CRIS) August 2026 public offering?

Curis priced a public offering of 3,733,334 shares (or pre-funded warrants) plus equal common warrants. According to Curis, the combined price is $1.50 per share and warrant, or $1.49 per pre-funded warrant and warrant, with gross proceeds expected around $5.6 million.

How much capital will Curis (CRIS) raise from its $5.6 million offering?

Curis expects gross proceeds of approximately $5.6 million from the offering. According to Curis, this figure is before deducting placement agent fees and estimated offering expenses, so net proceeds will be lower after transaction costs are paid.

What are the warrant terms in the Curis (CRIS) August 2026 equity offering?

Curis is issuing common warrants with a $1.75 exercise price, exercisable immediately for five years. According to Curis, pre-funded warrants have a $0.01 exercise price, are exercisable immediately, and remain outstanding until fully exercised, potentially adding more common shares.

How will Curis (CRIS) use the proceeds from its August 2026 public offering?

Curis plans to use net proceeds to fund research and development, working capital, and general corporate purposes. According to Curis, the capital from this approximately $5.6 million gross offering will support ongoing development of its programs and operational needs.

When is the Curis (CRIS) $5.6 million offering expected to close?

The offering is expected to close on or about August 14, 2026. According to Curis, completion is subject to market conditions and the satisfaction of customary closing conditions, which are typical requirements in registered public equity offerings.

Who are the placement agents for the Curis (CRIS) August 2026 public offering?

A.G.P./Alliance Global Partners is the lead placement agent and Laidlaw & Company (UK) is co-placement agent. According to Curis, these firms are handling placement of the shares, pre-funded warrants, and common warrants in the registered public offering.

Under which SEC registration is the Curis (CRIS) August 2026 offering being made?

The securities are offered under an effective Form S-1 registration statement, File No. 333-298203. According to Curis, the registration was filed on August 10, 2026 and declared effective by the SEC on August 12, 2026, enabling the public offering to proceed.